{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T04:18:41Z","timestamp":1792556321637,"version":"4.5.0"},"reference-count":59,"publisher":"Society of Nuclear Medicine","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2025,1,29]]},"published-print":{"date-parts":[[2025,5]]},"DOI":"10.2967\/jnumed.124.267730","type":"journal-article","created":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T16:15:15Z","timestamp":1740672915000},"page":"665-672","source":"Crossref","is-referenced-by-count":9,"title":["Treatment Landscape of Prostate Cancer in the Era of PSMA Radiopharmaceutical Therapy"],"prefix":"10.2967","volume":"66","author":[{"given":"Fabio","family":"Turco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Gillessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Paone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurelius","family":"Omlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2025,2,27]]},"reference":[{"key":"2025050105251678000_66.5.665.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040720"},{"key":"2025050105251678000_66.5.665.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041318"},{"key":"2025050105251678000_66.5.665.3","doi-asserted-by":"publisher","DOI":"10.2147\/RRU.S360444"},{"key":"2025050105251678000_66.5.665.4","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2003892"},{"key":"2025050105251678000_66.5.665.5","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.eururo.2020.08.011","article-title":"Apalutamide and overall survival in prostate cancer","volume":"79","author":"Smith","year":"2021","journal-title":"Eur Urol."},{"key":"2025050105251678000_66.5.665.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001342"},{"key":"2025050105251678000_66.5.665.7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70560-0"},{"key":"2025050105251678000_66.5.665.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503747"},{"key":"2025050105251678000_66.5.665.9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01037-5"},{"key":"2025050105251678000_66.5.665.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1704174"},{"key":"2025050105251678000_66.5.665.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1702900"},{"key":"2025050105251678000_66.5.665.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903835"},{"key":"2025050105251678000_66.5.665.13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00799"},{"key":"2025050105251678000_66.5.665.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903307"},{"key":"2025050105251678000_66.5.665.15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00367-1"},{"key":"2025050105251678000_66.5.665.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2119115"},{"key":"2025050105251678000_66.5.665.17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02437-5"},{"key":"2025050105251678000_66.5.665.18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303974"},{"key":"2025050105251678000_66.5.665.19","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.eururo.2024.09.017","article-title":"Management of patients with advanced prostate cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)","volume":"87","author":"Gillessen","year":"2025","journal-title":"Eur Urol."},{"key":"2025050105251678000_66.5.665.20","doi-asserted-by":"crossref","first-page":"140","DOI":"10.6004\/jnccn.2024.0019","article-title":"NCCN Guidelines\u00ae insights: prostate cancer, version 3.2024","volume":"22","author":"Schaeffer","year":"2024","journal-title":"J Natl Compr Canc Netw."},{"key":"2025050105251678000_66.5.665.21","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.eururo.2024.04.010","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. Part II-2024 update: treatment of relapsing and metastatic prostate cancer","volume":"86","author":"Tilki","year":"2024","journal-title":"Eur Urol."},{"key":"2025050105251678000_66.5.665.22","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.euo.2022.09.002","article-title":"Neoadjuvant 177Lu-PSMA-I&T radionuclide treatment in patients with high-risk prostate cancer before radical prostatectomy: a single-arm phase 1 trial","volume":"6","author":"Golan","year":"2023","journal-title":"Eur Urol Oncol."},{"key":"2025050105251678000_66.5.665.23","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.eururo.2023.08.026","article-title":"Administering [177Lu]Lu-PSMA-617 prior to radical prostatectomy in men with high-risk localised prostate cancer (LuTectomy): a single-centre, single-arm, phase 1\/2 study","volume":"85","author":"Eapen","year":"2024","journal-title":"Eur Urol."},{"key":"2025050105251678000_66.5.665.24","doi-asserted-by":"crossref","first-page":"5091","DOI":"10.1200\/JCO.2023.41.16_suppl.5091","article-title":"PSMA PET findings in an \u201cEMBARK-like\u201d cohort of patients with high-risk non-metastatic hormone-sensitive prostate cancer: a single center post-hoc retrospective analysis [abstract]","volume":"41","author":"Armstrong","year":"2023","journal-title":"J Clin Oncol."},{"key":"2025050105251678000_66.5.665.25","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1186\/s12885-023-10851-0","article-title":"The use of lutetium-177 PSMA radioligand therapy with high dose rate brachytherapy for locally recurrent prostate cancer after previous definitive radiation therapy: a randomized, single-institution, phase I\/II study (ROADSTER)","volume":"23","author":"Mendez","year":"2023","journal-title":"BMC Cancer."},{"key":"2025050105251678000_66.5.665.26","doi-asserted-by":"crossref","first-page":"102138","DOI":"10.1016\/j.clgc.2024.102138","article-title":"Hormonal agents in localized and advanced prostate cancer: current use and future perspectives","volume":"22","author":"Turco","year":"2024","journal-title":"Clin Genitourin Cancer."},{"key":"2025050105251678000_66.5.665.27","doi-asserted-by":"crossref","first-page":"4271","DOI":"10.1200\/JCO-24-01798","article-title":"Darolutamide in combination with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer from the phase III ARANOTE trial","volume":"42","author":"Saad","year":"2024","journal-title":"J Clin Oncol."},{"key":"2025050105251678000_66.5.665.28","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1056\/NEJMc2205310","article-title":"Darolutamide in metastatic prostate cancer","volume":"386","author":"Turco","year":"2022","journal-title":"N Engl J Med."},{"key":"2025050105251678000_66.5.665.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.09.008"},{"key":"2025050105251678000_66.5.665.30","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32486-3"},{"key":"2025050105251678000_66.5.665.31","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.eururo.2019.02.003","article-title":"Prostate radiotherapy for metastatic hormone-sensitive prostate cancer: a STOPCAP systematic review and meta-analysis","volume":"76","author":"Burdett","year":"2019","journal-title":"Eur Urol."},{"key":"2025050105251678000_66.5.665.32","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(24)01865-8","article-title":"Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2\u2009\u00d7\u20092 factorial design","volume":"404","author":"Bossi","year":"2024","journal-title":"Lancet."},{"key":"2025050105251678000_66.5.665.33","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1186\/s13063-021-05733-4","article-title":"Update to a randomized controlled trial of lutetium-177-PSMA in oligo-metastatic hormone-sensitive prostate cancer: the BULLSEYE trial","volume":"22","author":"Priv\u00e9","year":"2021","journal-title":"Trials."},{"key":"2025050105251678000_66.5.665.34","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S1470-2045(24)00440-6","article-title":"Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study","volume":"25","author":"Azad","year":"2024","journal-title":"Lancet Oncol."},{"key":"2025050105251678000_66.5.665.35","doi-asserted-by":"crossref","first-page":"TPS210","DOI":"10.1200\/JCO.2022.40.6_suppl.TPS210","article-title":"PSMAddition: a phase 3 trial to compare treatment with 177Lu-PSMA-617 plus standard of care (SOC) versus SOC alone in patients with metastatic hormone-sensitive prostate cancer [abstract]","volume":"40(suppl)","author":"Sartor","year":"2022","journal-title":"J Clin Oncol."},{"key":"2025050105251678000_66.5.665.36","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.529"},{"key":"2025050105251678000_66.5.665.37","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1050"},{"key":"2025050105251678000_66.5.665.38","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.eururo.2024.09.017","article-title":"Management of patients with advanced prostate cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)","volume":"87","author":"Gillessen","year":"2025","journal-title":"Eur Urol."},{"key":"2025050105251678000_66.5.665.39","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00382-0"},{"key":"2025050105251678000_66.5.665.40","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01649"},{"key":"2025050105251678000_66.5.665.41","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02704-x"},{"key":"2025050105251678000_66.5.665.42","doi-asserted-by":"crossref","first-page":"S1254","DOI":"10.1016\/j.annonc.2024.08.2307","article-title":"LBA1 A randomized multicenter open label phase III trial comparing enzalutamide vs a combination of radium-223 (Ra223) and enzalutamide in asymptomatic or mildly symptomatic patients with bone metastatic castration-resistant prostate cancer (mCRPC): first results of EORTC-GUCG 1333\/PEACE-3 [abstract]","volume":"35(suppl 2)","author":"Gillessen","year":"2024","journal-title":"Ann Oncol."},{"key":"2025050105251678000_66.5.665.43","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.5002"},{"key":"2025050105251678000_66.5.665.44","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1200\/JCO.2024.42.4_suppl.19","article-title":"BRCAAway: a randomized phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) bearing homologous recombination-repair mutations (HRRm) [abstract]","volume":"42(suppl)","author":"Hussain","year":"2024","journal-title":"J Clin Oncol."},{"key":"2025050105251678000_66.5.665.45","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","article-title":"177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial","volume":"404","author":"Morris","year":"2024","journal-title":"Lancet."},{"key":"2025050105251678000_66.5.665.46","doi-asserted-by":"crossref","first-page":"A1254","DOI":"10.1016\/j.annonc.2024.08.2308","article-title":"LBA65 Efficacy of 177Lu-PNT2002 in PSMA-positive mCRPC following progression on an androgen-receptor pathway inhibitor (ARPI) (SPLASH) [abstract]","volume":"35","author":"Sartor","year":"2024","journal-title":"Ann Oncol."},{"key":"2025050105251678000_66.5.665.47","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA2214676"},{"key":"2025050105251678000_66.5.665.48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911440"},{"key":"2025050105251678000_66.5.665.49","doi-asserted-by":"crossref","unstructured":"Rebuzzi SE Rescigno P Catalano F . Immune checkpoint inhibitors in advanced prostate cancer: current data and future perspectives. Cancers (Basel). 2022;14:1245.","DOI":"10.3390\/cancers14051245"},{"key":"2025050105251678000_66.5.665.50","doi-asserted-by":"crossref","first-page":"e2341165","DOI":"10.1001\/jamanetworkopen.2023.41165","article-title":"Antitumor activity and safety of dostarlimab monotherapy in patients with mismatch repair deficient solid tumors: a nonrandomized controlled trial","volume":"6","author":"Andre","year":"2023","journal-title":"JAMA. Netw Open."},{"key":"2025050105251678000_66.5.665.51","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02105"},{"key":"2025050105251678000_66.5.665.52","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"2025050105251678000_66.5.665.53","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1470-2045(23)00529-6","article-title":"Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial","volume":"25","author":"Hofman","year":"2024","journal-title":"Lancet Oncol."},{"key":"2025050105251678000_66.5.665.54","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00237-3"},{"key":"2025050105251678000_66.5.665.55","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1213755"},{"key":"2025050105251678000_66.5.665.56","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30408-5"},{"key":"2025050105251678000_66.5.665.57","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/94.19.1458"},{"key":"2025050105251678000_66.5.665.58","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62344-6"},{"key":"2025050105251678000_66.5.665.59","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.07.019"}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.124.267730","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T12:25:55Z","timestamp":1746102355000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.124.267730"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,27]]},"references-count":59,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5,1]]},"published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.2967\/jnumed.124.267730"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.124.267730","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,27]]}}}